Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton. Although the exact mechanisms underlying the pathogenesis of AS remain to be elucidated, the presence of human leucocyte antigen (HLA)-B27 is known to markedly increase its risk of development. Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and tumour necrosis factor (TNF) blockers. In recent years, the interleukin (IL)-23/IL-17 pathway has been shown to have significance in the pathogenesis of AS and treatment modalities targeting this pathway have been shown to be beneficial in various other inflammatory conditions. This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.

Original publication

DOI

10.1111/cei.12670

Type

Journal article

Journal

Clinical and experimental immunology

Publication Date

01/2016

Volume

183

Pages

30 - 36

Addresses

Oxford University Hospitals NHS Trust, Oxford, UK.

Keywords

Animals, Humans, Spondylitis, Ankylosing, Anti-Inflammatory Agents, Non-Steroidal, Interleukin-17, HLA-B27 Antigen, Immunotherapy, Signal Transduction, Interleukin-23, Molecular Targeted Therapy